The Food and Drug Administration (FDA) has expanded the approval for Evekeo ODT (amphetamine sulfate; Arbor Pharmaceuticals) to include patients 3 to 5 years of age for the treatment of attention deficit hyperactivity disorder (ADHD). Previously, the treatment was indicated for patients 6 to 17 years of age.